祛风止痉散在治疗支气管哮喘(哮病-风痰哮证)患者中对气道炎症及气道重塑的作用机制  

Effect of Qufeng Zhijing San on airway inflammation and airway remodelling in patients with bronchial asthma(asthma wind phlegm asthma syndrome)

作　　者：王玲 杨柳 展楠楠 姚龙龙 席磊 WANG Ling;YANG Liu;ZHAN Nannan;YAO Longlong;XI Lei(Xinjiang Uygur Autonomous Region Institute of Traditional Chinese Medicine;Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine,Urumqi 830000,China;Xinjian School of Traditional Chinese Medicine,Xinjiang Medical University,Urumqi 830017,China)

机构地区：[1]新疆维吾尔自治区中医药研究院 [2]新疆维吾尔自治区中医医院,乌鲁木齐830000 [3]新疆医科大学中医学院,乌鲁木齐830017

出　　处：《新疆医科大学学报》2024年第1期121-125,共5页Journal of Xinjiang Medical University

基　　金：新疆维吾尔自治区自然科学基金面上项目(2021D01C216)。

摘　　要：目的观察祛风止痉散对支气管哮喘(哮病-风痰哮证)患者细胞外信号调节蛋白激酶-1、2(Extracellular regulating kinase,ERK-1、ERK-2)、基质金属蛋白酶-9(Matrix metalloproteinase-9,MMP-9)、白细胞介素-6(Interleukin-6,IL-6)、白细胞介素-8(Interleukin-8,IL-8)、白细胞介素-13(Interleukin-13,IL-13)、白细胞介素-17(Interleukin-17,IL-17)、白细胞介素-32(Interleukin-32,IL-32)、血清类黏蛋白1样蛋白3基因(Orosomucoid1-like protein3,ORMDL3)的影响,探讨祛风止痉散对改善哮喘气道炎症的作用机制。方法选择2021年7月至2022年5月就诊于新疆维吾尔自治区中医医院确诊为支气管哮喘(哮病-风痰哮证)患者75例,按随机数字表法分为对照组(n=38)和作为试验组(n=37);同时选择同期健康体检者作为健康组(n=10)。对照组给予布地奈德福莫特罗粉吸入剂(160/4.5μg),每日2次,每次1吸;试验组在对照组基础上联合中药祛风止痉散口服;疗程3个月。健康组不予治疗。分别采用聚合酶链反应(Polymerase chain reaction,PCR)、酶联免疫吸附法(Enzyme linked immunosorbent assay,ELISA)检测并比较3组用药前后ERK-1、ERK-2、ORMDL-3、MMP-9、IL-6、IL-8、IL-13、IL-17、IL-32水平差异。结果治疗前,与健康组比较,对照组、试验组ORMDL-3、ERK-2、ERK-1水平明显升高,差异有统计学意义(P<0.05);与健康组比较,对照组、试验组MMP-9表达水平差异无统计学意义(P>0.05);与对照组比较,试验组ORMDL-3、ERK-2、ERK-1、MMP-9表达水平差异均无统计学意义(P>0.05)。治疗后,试验组与对照组IL-6、IL-8、IL-17、IL-32、ERK-1、ORMDL-3差异均无统计学意义(P>0.05),但试验组IL-13、ERK-2水平较对照组明显降低,差异有统计学意义(P<0.05)。结论祛风止痉散可能通过降低ERK-2和IL-13的表达水平,进而减轻支气管哮喘(哮病-风痰哮证)患者介导的炎症反应。Objective Observing the effects of Qufeng Zhijing San on extracellular signal regulated protein kinase-1,ERK-2,matrix metalloproteinase-9,IL-6,IL-8,and IL-13 in patients with bronchial asthma(asthma wind phlegm asthma syndrome).The effects of Interleukin-17(IL-17),Interleukin-32(IL-32)and serum Orosmucoid1-like protein 3(ORMDL3)genes on asthma airway inflammation were investigated,and the mechanism of Qufeng Zhijing San in improving asthma airway inflammation was explored.Methods 75 patients diagnosed with bronchial asthma(asthma wind phlegm asthma syndrome)who visited to the hospital from July 2021 to May 2022 were randomly divided into a control group(n=38)and an experimental group(n=37)using a random number table method.Simultaneously select individuals who underwent health examinations during the same period as health group(n=10).The control group was given budesonide fumoterol powder inhaler(160/4.5μg)twice a day,with one inhaler per session.The experimental group was orally administered in combination with traditional Chinese medicine(TCM)Qufeng Zhijing San on the basis of the control group.The treatment period was 3 months.The health group will not receive treatment.Polymerase chain reaction(PCR)and enzyme-linked immunosorbent assay(ELISA)were used to detect and compare the differences in ERK-1,ERK-2,ORMDL-3,MMP-9,IL-6,IL-8,IL-13,IL-17 and IL-32 levels among the 3 groups before and after the medication.Results Before the treatment,compared with the healthy group,the levels of ORMDL-3,ERK-2 and ERK-1 in the control group and experimental group were significantly increased,with statistical significance(P<0.05);Compared with the healthy group,there was no statistically significant difference in MMP-9 expression levels between control group and experimental group(P>0.05).Compared with control group,there was no statistically significant difference in the expression levels of ORMDL-3,ERK-2,ERK-1 and MMP-9 in the experimental group(P>0.05).After the treatment,there was no statistically significant difference be

关 键 词：祛风止痉散 支气管哮喘 细胞外信号调节蛋白激酶 白细胞介素 

分 类 号：R562.2[医药卫生—呼吸系统]